Consent to the Distribution of New Medicines Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution inNew Zealand of the new medicines set out in the Schedule hereto: Schedule Name and Strength Form Name and Address of Manufacturer Proprietary Name(if any) Sodium chloride 0.18% and 1.8% in 500 mL, 3.6% in 250 mL Solution for infusion (bottles) Biomed Laboratories Limited, Point Chevalier, Auckland Carboxymethylcellulose 1% w/v in 0.4 mL Solution (ophthalmic) Allergan Optical, Allergan Inc., Waco, Texas, United States of America and Allergan Pharmaceuticals (Ireland) Limited, Westport, County Mayo, Ireland Celluvisc Tacrine hydrochloride 10 mg, 20 mg, 30 mg, 40 mg Capsules Godecke AG., Freiburg, Germany Cognex Losartan potassium 50 mg Tablet Merck Sharp & Dohme Limited, Cramlington, Northumberland, England Cozaar Alendronate sodium 13.05 mg (equivalent to 10 mg alendronate) Tablet Merck Sharp & Dohme Italia SpA., Pavia, Italy Fosamax Tirilazad mesylate 1.5 mg/ mL in 30 mL, 70 mL and 100 mL Solution for infusion (vial) N V Upjohn SA., Puurs, Belgium Freedox Meropenem trihydrate 570 mg (equivalent to 500 mg anhydrous meropenem in 10 mL) and sodium carbonate 34.68 mg in 2 mL as diluent Powder for IM injection (vial) Sumitomo Pharmaceutical Co Limited, Ibaraki-Shi, Osaka, Japan and Zambon Group SpA., Vicenza, Italy (diluent only) Merrem IM Meropenem trihydrate 285 mg, 570 mg, 1.14 g (equivalent to 250 mg in 10 mL, 500 mg in 20 mL, 1 g in 30 mL anhydrous menopenem) Powder for IV injection (vial) Sumitomo Pharmaceutical Co Limited, Ibaraki-Shi, Osaka, Japan Merrem IV Abciximab 2 mg/ mL in 5 mL and 20 mL Solution for injection (vials) Centocor BV., Leiden, The Netherlands Reopro Sparfloxacin 100 mg, 200 mg Tablets Rhone Poulenc Rorer Pharmaceuticals Limited, Nenagh, Co. Tipperary, Republic of Ireland Zagam Dated this 12th day of September 1995. KAREN O. POUTASI, Director-General of Health, pursuant to delegation given by the Minister of Health on 25 June 1993.